Core Viewpoint - The company reported a year-on-year decline in total revenue of approximately 6.9% to about HKD 323 million for the six months ending September 30, 2025, primarily due to weakened sales performance in traditional Chinese medicine, Western medicine, and health food products [1] Financial Performance - The company recorded a profit attributable to shareholders of approximately HKD 2.8 million, a significant decrease from approximately HKD 23.7 million for the same period ending September 30, 2024 [1] - Earnings per share were reported at HKD 0.025 [1] Market and Sales Dynamics - The decline in revenue was attributed to weak consumer sentiment in the retail market, leading to a reduction in gross profit and a significant drop in net gains from property sales, as well as a decrease in fair value gains from investment properties [1] Product Innovation and Marketing - The company continues to commit to product innovation, successfully launching a marketing campaign combining outdoor and digital promotions for its popular health product, which has seen significant sales growth [1] - New marketing campaigns are planned for flagship products such as An Gong Niu Huang Wan and Hou Zao Chu Tan San for the upcoming autumn and winter seasons [1] Regulatory Developments - The company has been closely collaborating with relevant Chinese authorities following the announcement of simplified approval processes for traditional Chinese medicine in the Greater Bay Area [1] - The company announced that Hou Zao Chu Tan San has been approved as the first OTC product in Hong Kong under this new process, which will allow millions of consumers in mainland China to access the product conveniently starting next year [1]
位元堂(00897.HK)中期总收益同比减少约6.9%至约3.23亿港元